Can we predict dangerous blood clots in lymphoma patients? a major study aims to find out
NCT ID NCT06694779
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This study looks at how well existing risk models predict dangerous blood clots in people with diffuse large B-cell lymphoma (DLBCL), a common type of blood cancer. Researchers will review medical records from over 1,500 patients across multiple hospitals to see which factors are most linked to clots. The goal is to create a more accurate tool to help doctors decide who might benefit from clot-preventing medication.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a better way to identify lymphoma patients at high risk of blood clots, helping doctors decide who needs preventive treatment.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly test any new drug or therapy. The findings may not change practice immediately.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ivan Civettini
Monza, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can an immune booster outsmart brain lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can donor immune cells be engineered to fight blood cancer?
- Can a new device suck out deadly lung clots?
- Can a simple blood test spot lymphoma earlier?